ALGS
Price
$6.67
Change
+$0.23 (+3.57%)
Updated
Aug 21 closing price
Capitalization
41.65M
74 days until earnings call
Intraday BUY SELL Signals
AMLX
Price
$38.66
Change
-$1.00 (-2.52%)
Updated
Aug 21 closing price
Capitalization
4.31B
74 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALGS vs AMLX

ALGS vs AMLX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ALGS vs. AMLX commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALGS is a Hold and AMLX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 23, 2026
Stock price -- (ALGS: $6.67 vs. AMLX: $38.66)
Brand notoriety: ALGS and AMLX are both not notable
ALGS represents the Biotechnology, while AMLX is part of the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ALGS: 46% vs. AMLX: 136%
Market capitalization -- ALGS: $41.65M vs. AMLX: $4.31B
ALGS [@Biotechnology] is valued at $41.65M. AMLX’s [@Pharmaceuticals: Generic] market capitalization is $4.31B. The market cap for tickers in the [@Biotechnology] industry ranges from $138.91B to $0. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALGS’s FA Score shows that 1 FA rating(s) are green whileAMLX’s FA Score has 0 green FA rating(s).

  • ALGS’s FA Score: 1 green, 4 red.
  • AMLX’s FA Score: 0 green, 5 red.
According to our system of comparison, ALGS is a better buy in the long-term than AMLX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALGS’s TA Score shows that 5 TA indicator(s) are bullish while AMLX’s TA Score has 4 bullish TA indicator(s).

  • ALGS’s TA Score: 5 bullish, 5 bearish.
  • AMLX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ALGS and AMLX are a good buy in the short-term.

Price Growth

ALGS (@Biotechnology) experienced а -3.19% price change this week, while AMLX (@Pharmaceuticals: Generic) price change was +78.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +15.94%, and the average quarterly price growth was +3349.70%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.60%. For the same industry, the average monthly price growth was +6.53%, and the average quarterly price growth was +30.86%.

Reported Earning Dates

ALGS is expected to report earnings on Nov 05, 2026.

AMLX is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (+3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Pharmaceuticals: Generic (+1.60% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMLX($4.31B) has a higher market cap than ALGS($41.7M). AMLX YTD gains are higher at: 220.033 vs. ALGS (-28.433). ALGS has higher annual earnings (EBITDA): -92.52M vs. AMLX (-158.8M). AMLX has more cash in the bank: 280M vs. ALGS (54.9M). ALGS has less debt than AMLX: ALGS (4.35M) vs AMLX (5.63M). ALGS has higher revenues than AMLX: ALGS (4.71M) vs AMLX (0).
ALGSAMLXALGS / AMLX
Capitalization41.7M4.31B1%
EBITDA-92.52M-158.8M58%
Gain YTD-28.433220.033-13%
P/E RatioN/A2.69-
Revenue4.71M0-
Total Cash54.9M280M20%
Total Debt4.35M5.63M77%
FUNDAMENTALS RATINGS
ALGS: Fundamental Ratings
ALGS
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
44
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ALGSAMLX
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
73%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
Momentum
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 5 days ago
79%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 10 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
82%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
ALGS
Daily Signal:
Gain/Loss:
AMLX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ESCGX17.050.33
+1.97%
Ashmore Emerging Markets Focus Eq C
ALGCX16.900.25
+1.50%
Alger International Opportunities C
ERBAX20.360.10
+0.49%
Eaton Vance Equity Strategy A
SXPAX59.850.26
+0.44%
DWS S&P 500 Index A
FIQWX19.97N/A
N/A
Fidelity Advisor Strategic Div & Inc Z

ALGS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALGS has been loosely correlated with ABCL. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ALGS jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALGS
1D Price
Change %
ALGS100%
+3.57%
ABCL - ALGS
44%
Loosely correlated
-2.16%
ARVN - ALGS
41%
Loosely correlated
+3.77%
XNCR - ALGS
39%
Loosely correlated
+2.96%
EDIT - ALGS
38%
Loosely correlated
+5.78%
AMLX - ALGS
37%
Loosely correlated
-2.52%
More

AMLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMLX has been loosely correlated with OCUL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AMLX jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMLX
1D Price
Change %
AMLX100%
-2.52%
OCUL - AMLX
46%
Loosely correlated
-0.09%
LRMR - AMLX
45%
Loosely correlated
+0.48%
JAZZ - AMLX
43%
Loosely correlated
+2.24%
RGNX - AMLX
43%
Loosely correlated
-3.07%
IDYA - AMLX
43%
Loosely correlated
+1.43%
More